S. Kubicka

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.

A. Hinke, W. Schmiegel, H. Schmoll, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

S. Kubicka, R. Hofheinz, U. Hacker, 2016, Gastroenterology research and practice.

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis

R. Greil, A. Hinke, A. Grothey, 2005 .

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.

R. Greil, A. Hinke, A. Grothey, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.

R. Greil, A. Hinke, A. Grothey, 2008, Clinical colorectal cancer.

S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial

F. Lordick, J. Trojan, R. Greil, 2023, ESMO Open.